Immunovia

0.20 SEK

-5.58%

Less than 1K followers

IMMNOV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Immunovia

2019202020212022202320242025
Revenue0.40.40.81.21.60.90.7
growth-%1.7 %133.1 %36.3 %37.4 %-41.1 %-25.8 %
EBITDA-105.8-84.6-147.6-166.2-154.7-96.0-78.1
EBIT-114.2-134.3-166.6-191.2-296.5-109.4-80.4
Profit before taxes-114.5-146.0-156.0-168.1-309.4-76.5-145.9
Net income-114.5-146.0-156.0-168.1-309.4-76.5-145.9
EPS-2.10-2.45-2.47-2.66-3.07-0.72-0.42
Dividend0.000.000.000.000.000.000.00
Dividend ratio-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %

Profitability and return on capital

2019202020212022202320242025
EBITDA-%-29,719.7 %-23,359.1 %-17,484.0 %-14,455.7 %-9,793.7 %-10,321.5 %-11,313.0 %
EBIT-%-32,092.1 %-37,111.3 %-19,742.7 %-16,621.7 %-18,763.3 %-11,764.5 %-11,650.7 %
ROE-32.0 %-24.4 %-35.9 %-68.9 %-461.9 %-657.0 %-225.4 %
ROI-27.3 %-22.1 %-31.6 %-55.9 %-313.6 %-231.7 %-165.4 %